Scientists probe the Brain's 'Mystical' switch during psilocybin trips
NCT ID NCT07565493
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 1 time
Summary
This early-stage study at Johns Hopkins University is testing how blocking a specific brain receptor (5-HT1a) alters the effects of psilocybin, the active ingredient in magic mushrooms. Eighteen healthy volunteers will receive psilocybin with either pindolol (a receptor blocker) or a placebo, and researchers will measure their subjective experiences and brain activity using EEG. The goal is to better understand the biological mechanisms behind the psychedelic experience, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Psilocybin and pindolol
- What this could lead to
- If successful, this study could help scientists understand how psilocybin produces its mind-altering effects, potentially guiding future therapies for mental health conditions.
- What could go wrong
- This is a very small, early-phase study in healthy volunteers, not patients. It is designed to measure brain activity and subjective experiences, not to test a treatment. Results may not translate to clinical benefits.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSYCHEDELIC EFFECTS IN HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Center for Psychedelics and Consciousness Research
RECRUITINGBaltimore, Maryland, 21224-5010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.